$FLGT
Fulgent Genetics, Inc.

2020 Form 10-K Financial Statement

#000156459021011526 Filed on March 08, 2021

View on sec.gov

Income Statement

Concept 2020 2019 Q4 2019 Q3
Revenue $421.7M $8.387M $10.35M
YoY Change 1196.46% 47.84% 83.95%
Cost Of Revenue $89.81M $3.634M $3.885M
YoY Change 536.61% 31.24% 48.74%
Gross Profit $331.9M $4.753M $6.462M
YoY Change 1701.78% 63.67% 114.47%
Gross Profit Margin 78.7% 56.67% 62.45%
Selling, General & Admin $30.17M $3.367M $3.209M
YoY Change 145.02% 34.3% 32.55%
% of Gross Profit 9.09% 70.84% 49.66%
Research & Development $11.58M $1.795M $1.744M
YoY Change 77.15% 25.88% 21.28%
% of Gross Profit 3.49% 37.77% 26.99%
Depreciation & Amortization $2.962M $600.0K $503.0K
YoY Change 40.58% 0.0% -8.04%
% of Gross Profit 0.89% 12.62% 7.78%
Operating Expenses $41.75M $5.162M $4.953M
YoY Change 121.48% 31.25% 28.35%
Operating Profit $290.2M -$409.0K $1.509M
YoY Change -67893.93% -60.25% -278.37%
Interest Expense $20.00K $200.0K $200.0K
YoY Change -97.5% 100.0% 100.0%
% of Operating Profit 0.01% 13.25%
Other Income/Expense, Net
YoY Change
Pretax Income $291.7M -$160.0K $1.698M
YoY Change 71216.38% -82.81% -341.54%
Income Tax $72.53M -$38.00K $61.00K
% Of Pretax Income 24.87% 3.59%
Net Earnings $214.3M -$296.0K $1.462M
YoY Change -52243.55% -85.58% -345.71%
Net Earnings / Revenue 50.82% -3.53% 14.13%
Basic Earnings Per Share
Diluted Earnings Per Share $8.892M -$15.15K $76.92K
COMMON SHARES
Basic Shares Outstanding 22.69M 18.50M
Diluted Shares Outstanding 24.06M 19.46M

Balance Sheet

Concept 2020 2019 Q4 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $299.4M $28.27M $32.10M
YoY Change 957.95% -8.91% -1.54%
Cash & Equivalents $87.40M $11.97M $20.52M
Short-Term Investments $211.9M $16.30M $11.60M
Other Short-Term Assets $20.20M $2.255M $1.400M
YoY Change 1162.5% -11.95% -40.93%
Inventory
Prepaid Expenses $1.288M $1.160M
Receivables $185.2M $6.555M $5.400M
Other Receivables $18.90M $16.00K $27.00K
Total Short-Term Assets $523.6M $37.08M $39.20M
YoY Change 1311.32% -6.23% -4.51%
LONG-TERM ASSETS
Property, Plant & Equipment $41.00M $5.974M $9.100M
YoY Change 376.74% -7.32% 31.88%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $132.5M $872.0K $12.40M
YoY Change 209.58% -42.33% 610.19%
Other Assets $3.300M $251.0K $400.0K
YoY Change 1000.0% 1376.47% 2122.22%
Total Long-Term Assets $176.9M $51.68M $21.90M
YoY Change 242.17% 259.84% 59.27%
TOTAL ASSETS
Total Short-Term Assets $523.6M $37.08M $39.20M
Total Long-Term Assets $176.9M $51.68M $21.90M
Total Assets $700.5M $88.76M $61.10M
YoY Change 688.85% 64.66% 11.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $26.50M $1.581M $2.200M
YoY Change 1556.25% 20.41% 120.0%
Accrued Expenses $8.700M $1.333M $2.000M
YoY Change 383.33% 5.88% 66.67%
Deferred Revenue $365.0K
YoY Change 119.88%
Short-Term Debt $15.00M $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $130.1M $3.723M $4.253M
YoY Change 3416.22% 35.98% 84.91%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $600.0K $2.300M $2.400M
YoY Change -73.91% 16328.57% 21718.18%
Total Long-Term Liabilities $600.0K $2.300M $2.400M
YoY Change -73.91% 16328.57% 21718.18%
TOTAL LIABILITIES
Total Short-Term Liabilities $130.1M $3.723M $4.253M
Total Long-Term Liabilities $600.0K $2.300M $2.400M
Total Liabilities $131.1M $5.979M $6.619M
YoY Change 2085.0% 117.26% 187.78%
SHAREHOLDERS EQUITY
Retained Earnings -$63.43M -$63.13M
YoY Change 0.65%
Common Stock $146.1M $117.5M
YoY Change 27.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $569.4M $82.78M $54.53M
YoY Change
Total Liabilities & Shareholders Equity $700.5M $88.76M $61.15M
YoY Change 688.85% 64.66% 11.58%

Cashflow Statement

Concept 2020 2019 Q4 2019 Q3
OPERATING ACTIVITIES
Net Income $214.3M -$296.0K $1.462M
YoY Change -52243.55% -85.58% -345.71%
Depreciation, Depletion And Amortization $2.962M $600.0K $503.0K
YoY Change 40.58% 0.0% -8.04%
Cash From Operating Activities $140.6M -$100.0K $3.900M
YoY Change 2448.99% -112.5% -2050.0%
INVESTING ACTIVITIES
Capital Expenditures $35.13M -$500.0K -$100.0K
YoY Change 2872.08% 400.0% -90.0%
Acquisitions
YoY Change
Other Investing Activities -$291.3M -$35.70M $6.500M
YoY Change 944.09% 1387.5% 8.33%
Cash From Investing Activities -$326.4M -$36.00M $6.300M
YoY Change 1023.87% 1340.0% 26.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net -$246.1M
YoY Change 756.48%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 261.3M 27.70M 1.100M
YoY Change 807.91%
NET CHANGE
Cash From Operating Activities 140.6M -100.0K 3.900M
Cash From Investing Activities -326.4M -36.00M 6.300M
Cash From Financing Activities 261.3M 27.70M 1.100M
Net Change In Cash 75.46M -8.400M 11.30M
YoY Change 1343.12% 394.12% 135.42%
FREE CASH FLOW
Cash From Operating Activities $140.6M -$100.0K $3.900M
Capital Expenditures $35.13M -$500.0K -$100.0K
Free Cash Flow $105.5M $400.0K $4.000M
YoY Change 2333.63% -55.56% 400.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
Temple City
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
91780
CY2020 dei City Area Code
CityAreaCode
626
CY2020 dei Local Phone Number
LocalPhoneNumber
350-0537
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
40199000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
828000
CY2019Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
24000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
365000
CY2020Q4 flgt Investment Margin Liabilities Current
InvestmentMarginLiabilitiesCurrent
15019000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
267000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
420000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
130115000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3723000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
568000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2256000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
377000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
14000
CY2020Q4 us-gaap Liabilities
Liabilities
131074000
CY2019Q4 us-gaap Liabilities
Liabilities
5979000
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
418065000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
146058000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
438000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
146000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
150881000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-63429000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
569387000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
82777000
CY2019 us-gaap Cost Of Revenue
CostOfRevenue
14107000
CY2019 us-gaap Operating Expenses
OperatingExpenses
18849000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
290158000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-428000
CY2020 us-gaap Operating Expenses
OperatingExpenses
41747000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
72532000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
43000
CY2020 flgt Income Before Equity Net Income Loss In Investee And Impairment Loss
IncomeBeforeEquityNetIncomeLossInInvesteeAndImpairmentLoss
219152000
CY2019 flgt Income Before Equity Net Income Loss In Investee And Impairment Loss
IncomeBeforeEquityNetIncomeLossInInvesteeAndImpairmentLoss
366000
CY2020 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-488000
CY2019 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-777000
CY2020 us-gaap Equity Method Investment Other Than Temporary Impairment
EquityMethodInvestmentOtherThanTemporaryImpairment
4354000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-411000
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24056000
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18709000
CY2020 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
20000
CY2019 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-17000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
272000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
198000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
214602000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-230000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
51152000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3209000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
38000
CY2019 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
21000
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
181000
CY2020 us-gaap Profit Loss
ProfitLoss
214310000
CY2019 us-gaap Profit Loss
ProfitLoss
-411000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
8157000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
3209000
CY2020 us-gaap Depreciation
Depreciation
2962000
CY2019 us-gaap Depreciation
Depreciation
2107000
CY2020 flgt Noncash Lease Expense
NoncashLeaseExpense
409000
CY2019 flgt Noncash Lease Expense
NoncashLeaseExpense
413000
CY2020 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-672000
CY2019 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-11000
CY2020 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
857000
CY2019 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
106000
CY2020 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1170000
CY2019 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
189000
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1775000
CY2019 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-21000
CY2020 flgt Unrecognized Tax Benefits Operating Activities
UnrecognizedTaxBenefitsOperatingActivities
-377000
CY2020 flgt Holding Income Loss On Equity Securities
HoldingIncomeLossOnEquitySecurities
-90000
CY2020 flgt Impairment Income Loss In Equity Method Investment
ImpairmentIncomeLossInEquityMethodInvestment
-4354000
CY2020 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-8000
CY2019 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-52000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
178480000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
839000
CY2020 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
21149000
CY2019 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-374000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
22617000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-329000
CY2020 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
32655000
CY2019 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
264000
CY2020 us-gaap Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable
53295000
CY2019 us-gaap Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable
24000
CY2020 flgt Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-389000
CY2019 flgt Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-409000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
140628000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
5517000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
35130000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1182000
CY2020 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
8000
CY2020 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
324359000
CY2019 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
52077000
CY2020 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
19919000
CY2019 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
24350000
CY2020 flgt Payments For Purchase Of Equipment Contributed To Equity Method Investee
PaymentsForPurchaseOfEquipmentContributedToEquityMethodInvestee
1380000
CY2019 flgt Payments For Purchase Of Equipment Contributed To Equity Method Investee
PaymentsForPurchaseOfEquipmentContributedToEquityMethodInvestee
137000
CY2020 flgt Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
17095000
CY2020 us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
2591000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-326438000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-29046000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
246190000
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
28758000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
104000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
38000
CY2020 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
62000
CY2019 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
21000
CY2020 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
15019000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
261251000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
28775000
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20000
CY2019 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-17000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
75461000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5229000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11965000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6736000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
87426000
CY2020 us-gaap Income Taxes Paid
IncomeTaxesPaid
20612000
CY2019 us-gaap Income Taxes Paid
IncomeTaxesPaid
20000
CY2020 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
3402000
CY2019 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
557000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
402000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
110000
CY2020 flgt Noncash Or Part Noncash Operating Lease Liabilities Removed Due To Purchasing Of Underlying Assets
NoncashOrPartNoncashOperatingLeaseLiabilitiesRemovedDueToPurchasingOfUnderlyingAssets
1853000
CY2020 flgt Noncash Or Part Noncash Public Offering Proceeds In Other Receivable Included In Other Current Assets
NoncashOrPartNoncashPublicOfferingProceedsInOtherReceivableIncludedInOtherCurrentAssets
17799000
CY2020 flgt Noncash Or Part Noncash Public Offering Costs Included In Accounts Payable
NoncashOrPartNoncashPublicOfferingCostsIncludedInAccountsPayable
359000
CY2019 flgt Noncash Or Part Noncash Public Offering Costs Included In Accounts Payable
NoncashOrPartNoncashPublicOfferingCostsIncludedInAccountsPayable
129000
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting periods. These estimates, judgments and assumptions are based on historical data and experience available at the date of the accompanying consolidated financial statements, as well as various other factors management believes to be reasonable under the circumstances, including but not limited to the potential impacts arising from the recent global pandemic related to COVID-19. As the extent and duration of the impacts from COVID-19 remain unclear, the Company&#8217;s estimates and assumptions may evolve as conditions change. Actual results could differ significantly from these estimates.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On an on-going basis, management evaluates its estimates, primarily those related to: (i) revenue recognition criteria, (ii) accounts receivable and allowances for doubtful accounts, (iii) the useful lives of fixed assets, (iv) estimates of tax liabilities and (v) valuation of equity method investments.</p>
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations of Credit Risk, Customers and Suppliers</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable and marketable securities, which consist of debt securities and equity securities. As of December&#160;31, 2020, substantially all of the Company&#8217;s cash and cash equivalents were deposited in accounts at financial institutions, and amounts may exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institutions in which its cash and cash equivalents are held.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In certain periods, a small number of customers has accounted for a significant portion of the Company&#8217;s revenue. Aggregating customers that are under common control or are affiliates, two customers comprised 28% and 10% of total revenue in the year ended December 31, 2020, and one customer comprised 28% of total revenue in the year ended December 31, 2019. No customer comprised at least 10% of total accounts receivable as of December 31, 2020 and 2019.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue from the U.S. government was less than 10% of total revenue in each of the years ended December 31, 2020 and 2019.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company relies on a limited number of suppliers for its test collection kits and certain laboratory substances used in the chemical reactions incorporated into its processes, referred to as reagents, as well as for the sequencers and various other equipment and materials it uses in its laboratory operations. In particular, the Company relies on a sole supplier for the next generation sequencers and associated reagents it uses to perform its genetic tests and as the sole provider of maintenance and repair services for these sequencers. The Company&#8217;s laboratory operations would be interrupted if it encountered delays or difficulties securing these test collection kits, reagents, sequencers, other equipment or materials or maintenance and repair services, which could occur for a variety of reasons, including if the Company needs a replacement or temporary substitute for any of its limited or sole suppliers and is not able to locate and make arrangements with an acceptable replacement or temporary substitute. The Company believes there are currently only a few other manufacturers that are capable of supplying and servicing some of the equipment and other materials necessary for its laboratory operations, including collection kits, sequencers and various associated reagents. </p>
CY2019Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
0
CY2020Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
0
CY2019Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
0
CY2020Q4 flgt Fair Value Assets Transfers Between Levels Amount
FairValueAssetsTransfersBetweenLevelsAmount
0
CY2019Q4 flgt Fair Value Assets Transfers Between Levels Amount
FairValueAssetsTransfersBetweenLevelsAmount
0
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0
CY2020 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2019 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2019 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
us-gaap:AccountingStandardsUpdate201602Member
CY2018Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
590000
CY2020 flgt Bad Debt Expense
BadDebtExpense
1170000
CY2019 flgt Bad Debt Expense
BadDebtExpense
189000
CY2020 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
23000
CY2019 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
28000
CY2020 flgt Securities Maturity Period
SecuritiesMaturityPeriod
P3Y
CY2020 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2020 flgt Number Of Customer Types
NumberOfCustomerTypes
3
CY2020 flgt Tax Effects Related To Unrealized Holding Gains On Marketable Debt Securities
TaxEffectsRelatedToUnrealizedHoldingGainsOnMarketableDebtSecurities
147000
CY2020 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
257000
CY2019 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
59000
CY2020 us-gaap Revenue Practical Expedient Remaining Performance Obligation
RevenuePracticalExpedientRemainingPerformanceObligation
true
CY2020 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
us-gaap:AccountingStandardsUpdate201815Member
CY2020Q4 us-gaap Change In Accounting Principle Accounting Standards Update Adopted
ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
true
CY2020Q4 us-gaap Change In Accounting Principle Accounting Standards Update Immaterial Effect
ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
true
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
47461000
CY2020Q4 flgt Available For Sale Securities Debt Equity Securities And Trading Securities Amortized Cost Basis
AvailableForSaleSecuritiesDebtEquitySecuritiesAndTradingSecuritiesAmortizedCostBasis
343987000
CY2020Q4 flgt Available For Sale Securities Debt Equity Securities And Trading Securities Unrealized Gain Before Tax
AvailableForSaleSecuritiesDebtEquitySecuritiesAndTradingSecuritiesUnrealizedGainBeforeTax
754000
CY2020Q4 flgt Available For Sale Securities Debt Equity Securities And Trading Securities Unrealized Loss Before Tax
AvailableForSaleSecuritiesDebtEquitySecuritiesAndTradingSecuritiesUnrealizedLossBeforeTax
298000
CY2020Q4 flgt Available For Sale Securities Debt Equity Securities And Trading Securities
AvailableForSaleSecuritiesDebtEquitySecuritiesAndTradingSecurities
344443000
CY2019Q4 flgt Available For Sale Securities Debt Equity Securities And Trading Securities Amortized Cost Basis
AvailableForSaleSecuritiesDebtEquitySecuritiesAndTradingSecuritiesAmortizedCostBasis
58124000
CY2019Q4 flgt Available For Sale Securities Debt Equity Securities And Trading Securities Unrealized Gain Before Tax
AvailableForSaleSecuritiesDebtEquitySecuritiesAndTradingSecuritiesUnrealizedGainBeforeTax
159000
CY2019Q4 flgt Available For Sale Securities Debt Equity Securities And Trading Securities Unrealized Loss Before Tax
AvailableForSaleSecuritiesDebtEquitySecuritiesAndTradingSecuritiesUnrealizedLossBeforeTax
32000
CY2019Q4 flgt Available For Sale Securities Debt Equity Securities And Trading Securities
AvailableForSaleSecuritiesDebtEquitySecuritiesAndTradingSecurities
58251000
CY2020 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
298000
CY2019 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
32000
CY2020Q4 flgt Marketable Securities Interest Receivable Current
MarketableSecuritiesInterestReceivableCurrent
1016000
CY2019Q4 flgt Marketable Securities Interest Receivable Current
MarketableSecuritiesInterestReceivableCurrent
478000
CY2020Q4 us-gaap Prepaid Taxes
PrepaidTaxes
14000
CY2019Q4 us-gaap Prepaid Taxes
PrepaidTaxes
46000
CY2020 us-gaap Payments To Acquire Real Estate
PaymentsToAcquireRealEstate
15400000
CY2020 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
131000
CY2020 flgt Proceeds From Sale Of Marketable Equity Securities
ProceedsFromSaleOfMarketableEquitySecurities
9000000
CY2020 us-gaap Equity Securities Fv Ni Realized Gain
EquitySecuritiesFvNiRealizedGain
24000
CY2020 us-gaap Equity Securities Fv Ni Unrealized Loss
EquitySecuritiesFvNiUnrealizedLoss
89000
CY2019 flgt Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
0
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
2000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
1000
CY2020 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
8100000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
917000
CY2020Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
61612
CY2020Q4 us-gaap Area Of Land
AreaOfLand
2.6
CY2020Q4 flgt Refundable Deposits
RefundableDeposits
350000
CY2020 flgt Payments For Remaining Deposit Amount Owed
PaymentsForRemainingDepositAmountOwed
15000000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
51119000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
13964000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10920000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
82000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
835000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7990000
CY2020Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
17810000
CY2019Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
16000
CY2019 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
0
CY2020 us-gaap Operating Lease Lease Income Lease Payments
OperatingLeaseLeaseIncomeLeasePayments
144000
CY2020 us-gaap Operating Lease Variable Lease Income
OperatingLeaseVariableLeaseIncome
1000
CY2020 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
145000
CY2020Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
1379000
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3000000
CY2019Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
384000
CY2020Q4 flgt Reagents And Supplies Current
ReagentsAndSuppliesCurrent
16491000
CY2019Q4 flgt Reagents And Supplies Current
ReagentsAndSuppliesCurrent
277000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3682000
CY2020 flgt Payments For Closing Of Escrow Financed Under Margin Loan
PaymentsForClosingOfEscrowFinancedUnderMarginLoan
15000000
CY2020 flgt Debt Instrument Interest Rate At Beginning Of Period
DebtInstrumentInterestRateAtBeginningOfPeriod
0.01
CY2020 flgt Debt Instrument Interest Rate At End Of Period
DebtInstrumentInterestRateAtEndOfPeriod
0.0078
CY2020 us-gaap Interest Expense
InterestExpense
20000
CY2020Q4 us-gaap Purchase Obligation
PurchaseObligation
27600000
CY2020 flgt Operating Leases Term Of Expiration
OperatingLeasesTermOfExpiration
2025-10
CY2020Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P3Y
CY2019Q4 us-gaap Change In Accounting Principle Accounting Standards Update Adopted
ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
true
CY2019Q4 us-gaap Change In Accounting Principle Accounting Standards Update Adoption Date
ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
2019-01-01
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
566000
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
587000
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1288000
CY2020 us-gaap Short Term Lease Cost
ShortTermLeaseCost
142000
CY2019Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
150000
CY2020 us-gaap Lease Cost
LeaseCost
708000
CY2019 us-gaap Lease Cost
LeaseCost
587000
CY2020 flgt Cash Paid For Amounts Included In Measurement Of Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities
801000
CY2019 flgt Cash Paid For Amounts Included In Measurement Of Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities
535000
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0622
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
311000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
309000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
270000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
24000
CY2020Q4 us-gaap Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
335000
CY2020Q4 us-gaap Lessor Operating Lease Payments To Be Received Two Years
LessorOperatingLeasePaymentsToBeReceivedTwoYears
190000
CY2020Q4 us-gaap Lessor Operating Lease Payments To Be Received Three Years
LessorOperatingLeasePaymentsToBeReceivedThreeYears
95000
CY2020Q4 us-gaap Lessor Operating Lease Payments To Be Received Four Years
LessorOperatingLeasePaymentsToBeReceivedFourYears
61000
CY2020Q4 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
681000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8157000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3209000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
291739000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
679000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-55000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-270000
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
53794000
CY2019 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
5000
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
20513000
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-248000
CY2019 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
38000
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
74307000
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
43000
CY2019 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-249000
CY2020 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-14000
CY2019 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-280000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1513000
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-529000
CY2020 flgt Deferred Income Tax Expense Benefit Including Of Change In Valuation Allowance
DeferredIncomeTaxExpenseBenefitIncludingOfChangeInValuationAllowance
-1775000
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0568
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.4676
CY2020 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.0000
CY2019 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.1383
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.0013
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.0000
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.0092
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.5353
CY2020 flgt Effective Income Tax Rate Reconciliation Return To Provision
EffectiveIncomeTaxRateReconciliationReturnToProvision
-0.0011
CY2019 flgt Effective Income Tax Rate Reconciliation Return To Provision
EffectiveIncomeTaxRateReconciliationReturnToProvision
-0.5711
CY2020 flgt Effective Income Tax Rate Reconciliation Other Permanent Differences
EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences
0.0002
CY2019 flgt Effective Income Tax Rate Reconciliation Other Permanent Differences
EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences
0.0387
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0041
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0001
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.0052
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
1.2922
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.2487
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.1053
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
166000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
97000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
513000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
180000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
206000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
445000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1424000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
609000
CY2020Q4 us-gaap Deferred Tax Assets State Taxes
DeferredTaxAssetsStateTaxes
4306000
CY2019Q4 us-gaap Deferred Tax Assets State Taxes
DeferredTaxAssetsStateTaxes
8000
CY2020Q4 flgt Deferred Tax Assets Foreign Taxes
DeferredTaxAssetsForeignTaxes
1220000
CY2019Q4 flgt Deferred Tax Assets Foreign Taxes
DeferredTaxAssetsForeignTaxes
545000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
680000
CY2020Q4 flgt Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
226000
CY2019Q4 flgt Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
643000
CY2020Q4 us-gaap Deferred Tax Assets Equity Method Investments
DeferredTaxAssetsEquityMethodInvestments
700000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
89000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
8850000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
3207000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2021000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2125000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
6829000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1082000
CY2020Q4 flgt Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
4830000
CY2019Q4 flgt Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
419000
CY2020Q4 flgt Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
224000
CY2019Q4 flgt Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
633000
CY2020Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
147000
CY2019Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
30000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
5201000
CY2019Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8387000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10347000
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8424000
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5370000
CY2020Q4 us-gaap Cost Of Revenue
CostOfRevenue
51772000
CY2020Q3 us-gaap Cost Of Revenue
CostOfRevenue
26261000
CY2020Q2 us-gaap Cost Of Revenue
CostOfRevenue
7717000
CY2019Q4 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1635000
CY2019Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1687000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1082000
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
1628000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
141000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
236000
CY2020Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
377000
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2019Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2020 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2019 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
422000
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
237000
CY2020Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
294978000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
101716000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17265000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7753000
CY2020Q1 us-gaap Cost Of Revenue
CostOfRevenue
4057000
CY2019Q4 us-gaap Cost Of Revenue
CostOfRevenue
3634000
CY2019Q3 us-gaap Cost Of Revenue
CostOfRevenue
3885000
CY2019Q2 us-gaap Cost Of Revenue
CostOfRevenue
3620000
CY2019Q1 us-gaap Cost Of Revenue
CostOfRevenue
2968000
CY2020Q4 us-gaap Gross Profit
GrossProfit
243206000
CY2020Q3 us-gaap Gross Profit
GrossProfit
75455000
CY2020Q2 us-gaap Gross Profit
GrossProfit
9548000
CY2020Q1 us-gaap Gross Profit
GrossProfit
3696000
CY2019Q4 us-gaap Gross Profit
GrossProfit
4753000
CY2019Q3 us-gaap Gross Profit
GrossProfit
6462000
CY2019Q2 us-gaap Gross Profit
GrossProfit
4804000
CY2019Q1 us-gaap Gross Profit
GrossProfit
2402000
CY2020Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4576000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3177000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1849000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1978000
CY2019Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1795000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1744000
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1574000
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1424000
CY2020Q4 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5081000
CY2020Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5014000
CY2020Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3260000
CY2020Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1597000
CY2019Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1304000
CY2019Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1272000
CY2020Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7640000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3741000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1799000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2035000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-1956000
CY2019Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1732000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1522000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1631000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1529000
CY2020Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
225909000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
63523000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
2640000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1914000
CY2019Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-409000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
1509000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
295000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1823000
CY2020Q4 us-gaap Interest And Other Income
InterestAndOtherIncome
589000
CY2020Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
421000
CY2020Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
275000
CY2020Q4 flgt Income Before Equity Net Income Loss In Investee And Impairment Loss
IncomeBeforeEquityNetIncomeLossInInvesteeAndImpairmentLoss
167927000
CY2020Q3 flgt Income Before Equity Net Income Loss In Investee And Impairment Loss
IncomeBeforeEquityNetIncomeLossInInvesteeAndImpairmentLoss
49418000
CY2020Q2 flgt Income Before Equity Net Income Loss In Investee And Impairment Loss
IncomeBeforeEquityNetIncomeLossInInvesteeAndImpairmentLoss
3514000
CY2020Q1 flgt Income Before Equity Net Income Loss In Investee And Impairment Loss
IncomeBeforeEquityNetIncomeLossInInvesteeAndImpairmentLoss
-1707000
CY2019Q4 flgt Income Before Equity Net Income Loss In Investee And Impairment Loss
IncomeBeforeEquityNetIncomeLossInInvesteeAndImpairmentLoss
-122000
CY2020Q4 us-gaap Operating Expenses
OperatingExpenses
17297000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
11932000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
6908000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
5610000
CY2019Q4 us-gaap Operating Expenses
OperatingExpenses
5162000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
4953000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
4509000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
4225000
CY2020Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
241000
CY2019Q4 us-gaap Interest And Other Income
InterestAndOtherIncome
249000
CY2019Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
189000
CY2019Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
192000
CY2019Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
207000
CY2020Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
226498000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
63944000
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
2915000
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1673000
CY2019Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-160000
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1698000
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
487000
CY2019Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1616000
CY2020Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
58571000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
14526000
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-599000
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
34000
CY2019Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-38000
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
61000
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7000
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13000
CY2019Q3 flgt Income Before Equity Net Income Loss In Investee And Impairment Loss
IncomeBeforeEquityNetIncomeLossInInvesteeAndImpairmentLoss
1637000
CY2019Q2 flgt Income Before Equity Net Income Loss In Investee And Impairment Loss
IncomeBeforeEquityNetIncomeLossInInvesteeAndImpairmentLoss
480000
CY2019Q1 flgt Income Before Equity Net Income Loss In Investee And Impairment Loss
IncomeBeforeEquityNetIncomeLossInInvesteeAndImpairmentLoss
-1629000
CY2020Q4 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
143000
CY2020Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-189000
CY2020Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-193000
CY2020Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-249000
CY2019Q4 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-174000
CY2019Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-175000
CY2019Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-149000
CY2019Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-279000
CY2020Q4 us-gaap Equity Method Investment Other Than Temporary Impairment
EquityMethodInvestmentOtherThanTemporaryImpairment
1763000
CY2020Q3 us-gaap Equity Method Investment Other Than Temporary Impairment
EquityMethodInvestmentOtherThanTemporaryImpairment
2591000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
46638000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
3321000
CY2019Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.08
CY2019Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.02
CY2019Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.10
CY2020Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
1.98
CY2020Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.14
CY2020Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.09
CY2019Q4 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.01
CY2019Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.08
CY2019Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.02
CY2019Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.10
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-296000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
1462000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
331000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-1908000
CY2020Q4 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
6.55

Files In Submission

Name View Source Status
0001564590-21-011526-index-headers.html Edgar Link pending
0001564590-21-011526-index.html Edgar Link pending
0001564590-21-011526.txt Edgar Link pending
0001564590-21-011526-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
flgt-10k_20201231.htm Edgar Link pending
flgt-20201231.xml Edgar Link completed
flgt-20201231.xsd Edgar Link pending
flgt-20201231_cal.xml Edgar Link unprocessable
flgt-20201231_def.xml Edgar Link unprocessable
flgt-20201231_lab.xml Edgar Link unprocessable
flgt-20201231_pre.xml Edgar Link unprocessable
flgt-ex1034_88.htm Edgar Link pending
flgt-ex1035_90.htm Edgar Link pending
flgt-ex1036_89.htm Edgar Link pending
flgt-ex1037_91.htm Edgar Link pending
flgt-ex1038_92.htm Edgar Link pending
flgt-ex231_7.htm Edgar Link pending
flgt-ex311_9.htm Edgar Link pending
flgt-ex312_6.htm Edgar Link pending
flgt-ex321_10.htm Edgar Link pending
g0ysjx1apuid000001.jpg Edgar Link pending
glkm042yn2b0000001.jpg Edgar Link pending
gyyqebvlbfzc000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending